Multiple Myeloma: Lytic Bone Lesions of the Skull

Umberto G. Rossi¹, Anna Maria Ierardi², Maurizio Cariati³

Acta Neurol Taiwan 2021;30:83-84

A 77-year-old woman with a 1 years history of Multiple Myeloma (MM) presented with headache, fatigue, and bone pain. She underwent whole body multi-detector computed tomographic (MD-CT) to evaluate possible lytic bone lesions. MD-CT showed small, multiple osteolytic lesions, particularly at the skull level (Figure 1, 2).

MM is a plasma cell disorder. It is characterized by the monoclonal proliferation of malignant plasma cells ^(1,2). These cells, among their various characteristics, determine an infiltrate haemopoietic locations ⁽¹⁾. Pathogenesis of MM related bone disease is the uncoupling of the bone remodelling process. There is an increased activity of osteoclastogenesis with the suppressed osteoblastic one, resulting in bone loss ⁽¹⁻³⁾. This process creates lytic lesions without reactive bone formation ⁽²⁾. Bone disease could be from single lytic lesion to multiple lytic lesions affecting any part of skeleton, preferably skull, spine and long bones ⁽³⁾. MD-CT, with dedicated low-dose protocols, is able to provide whole body skeletal volume information with a greater sensitivity than conventional X-ray studies in MM patients ⁽³⁾. Whole body CT with low-dose protocols can detect lesions with less than 5% trabecular bone destruction, and it is the first-line diagnostic imaging procedure for the diagnosis of lytic bone disease in patients affected by MM ⁽⁴⁾.

When skull is involved, its most common MD-CT presentation is by numerous, well-circumscribed and punched-out lytic bone lesions, without reactive bone formation and diffuse osteopenia⁽¹⁻⁵⁾, as in the case presented.

REFERENCES

 Ugga L, Cuocolo R, Cocozza S, Ponsiglione A, Stanzione A, Chianca V, D'Amico A, Brunetti A, Imbriaco M. Spectrum of lytic lesions of the skull: a pictorial essay. Insights Imaging 2018, 9(5): 845-856.

- Andreu-Arasa VC, Chapman MN, Kuno H, Fujita A, Sakai O. Craniofacial manifestations of systemic disorders: CT and MR imaging findings and imaging approach. Radiographics 2018, 38: 890-911.
- 3. Hameed A, Brady JJ, Dowling P, Clynes M, O'Gorman P. Bone disease in multiple myeloma: pathophysiology

Correspondence to: Umberto G. Rossi, MD, EBIR. Email: urossi76@hotmail.com - umberto.rossi@galliera.it

From the 1Department of Diagnostic Imaging - Interventional Radiology Unit Ente Ospedaliero Galliera Hospital Mura delle Cappuccine, 14-16128 Genova, ITALY. 2Department of Diagnostic Imaging-Radiology Unit I.R.C.C.S. Cà Granda Fondation. Maggiore Policlinico Hospital, Via Francesco Sforza, 28-20122 Milano, Italy. 3Department of Diagnostic and Therapeutic Advanced Technology-Diagnostic and Interventional Radiology Unit Azienda Socio Sanitaria Territoriale Santi Paolo and Carlo Hospital Via A di Rudinì, 8-Via Pio II, 3-20100 Milano, ITALY.

Received April 14, 2020. Revised April 22, 2020. Accepted April 20, 2021.




Fig. 1. Multi-detector computed tomographic axial image (bone window) at the level of the skull vault that demonstrates small, round, multiple, well-circumscribed lytic bone lesions and diffuse osteopenia.

Fig. 2. Multi-detector computed tomographic sagittal Volume Rendering Technique (VRT) image reconstruction of the head that confirms small, round, multiple, well-circumscribed punched-out lytic bone lesions varying in shape and size at the level of skull and mandible.

and management. Cancer Growth Metastasis 2014; 7: 33-42.

- Ormond Filho AG, Carneiro BC, Pastore D, Silva IP, Yamashita SR, Consolo FD, Hungria VTM, Sandes AF, Rizzatti EG, Nico MAC. Whole-Body Imaging of Multiple Myeloma: Diagnostic Criteria. Radiographics. 2019; 39(4): 1077-1097.
- 5. Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M,

Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, Dimopoulos MA, Lentzsch S, Durie B, Terpos E. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J 2017, 7(8): e599.